Sucampo Pharmaceuticals is a worldwide pharmaceutical company engaged in the innovative research, discovery, development and commercialization of proprietary drugs based on prostones. Sucampo Chairman, CEO and Co-founder Ryuji Ueno, M.D., Ph.D., was the first person to identify the therapeutic potential of prostones, which are naturally occurring fatty acid metabolites. Prostones have emerged as promising compounds with unique physiological activities and can be targeted for treating unmet or underserved medical needs. For more information, visit the company’s Web site at www.sucampo.com.

The BIO CEO & Investor Conference is the largest investor conference focused on established and emerging publicly traded biotech companies. Each year the annual event provides a neutral forum where institutional investors, industry analysts, and senior biotechnology executives have the opportunity to shape the future investment landscape of the biotechnology industry. For more information on Biotechnology Industry Organization (BIO), visit www.bio.org.

Let us hear your thoughts below: